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Abstract
Vitamin D is necessary in maintaining appropriate calcium and phosphate homeostasis in the body (classical function) and ensuring
appropriate functioning of many tissues, organs and cells, unrelated to mineral economy (non-classical function). Vitamin D deficiency in
adults may cause osteomalacia, increase fracture risk in osteoporosis, induce cardiovascular diseases, diabetes type 1 and 2, multiple
sclerosis, Lesniowski-Crohn disease, and cancer, including colon, breast, and prostate cancer.
Possible causes of vitamin D deficiency in a healthy population include decreased cutaneous synthesis and an inadequate intake of vita-
min D, both in food and in supplements. Vitamin D deficiency level (25(OH) D. < 20 ng/mL), is fairly widespread, being found in
a substantial percentage of healthy subjects around the world, regardless of race, gender and age. Daily vitamin D dose, as determined by
the Food and Nutrition Board in 1997, is now rather insufficient, the biggest problem being associated with maximal vitamin D levels
(50 µg/day) in actually available food supplements. Nowadays, it is recommended that adults need a minimum of 800–1,000 U/day when their
exposure to the sun is inadequate (in Poland from October to April). This dosage should be provided to all subjects who avoid sunlight, as well
as to those aged over 65 because of their slower skin synthesis of vitamin D and for its proven anti-fracture and anti-fall effects.
(Pol J Endocrinol 2010; 61 (6): 723–729)
Key words: vitamin D, food inadequacy, supplementation
Streszczenie
Witamina D jest niezbędnym elementem do utrzymania właściwej homeostazy wapniowo-fosforanowej organizmu (rola klasyczna)
i zapewnienia właściwego funkcjonowania wielu tkanek, narządów i komórek niezależnych od obrotu mineralnego (rola nieklasyczna).
Niedobór witaminy D u dorosłych zwiększa ryzyko złamań kości w osteoporozie, może prowadzić do osteomalacji, choroby niedokrwiennej
serca, cukrzycy typu 1 i 2, stwardnienia rozsianego, choroby Leśniowskiego-Crohna oraz nowotworów szczególnie jelita grubego, piersi
i prostaty.
Przyczynami niedoboru witaminy D u zdrowej populacji jest prawdopodobnie zmniejszenie syntezy skórnej oraz niedostateczne spoży-
wanie w diecie oraz suplementach. Niedobór witaminy 25(OH)D (stężenie < 20 ng/ml) występuje dość powszechnie u zdrowej populacji
ogólnej niezależnie od rasy, płci i wieku. Dzienne zapotrzebowanie na witaminę D określone przez Food and Nutrition Board w 1997 roku,
jest obecnie niewystarczająca. Najwiekszy problem wiąże się z maksymalnym stężeniem witaminy D (50 µg/dobę) w suplementach. Obecnie
uważa się, że dzienne zapotrzebowanie osoby dorosłej wynosi 800–1000 j., jeżeli jej ekspozycja na słońce jest niewystarczająca (w Polsce od
października do kwietnia). Taka dawka powinna być przyjmowana przez osoby unikające nasłonecznienia, jak również stosowana przez
wszystkich w wieku powyżej 65 lat z powodu spowolnienia skórnej syntezy witaminy D, oraz ze względu na udowodnione działanie
przeciw złamaniom i upadkom. (Endokrynol Pol 2010; 61 (6): 723–729)
Słowa kluczowe: witamina D, niedobór w diecie, suplementacja
The guidelines concerning vitamin D supplementation in adults have been approved by:
National Consultant for Internal Medicine — Assistant Prof. Jacek Imiela MD, PhD
National Consultant for Family Medicine — Prof. Witold Lukas MD, PhD
Chairman of the Polish Foundation of Osteoporosis — Prof. Janusz Badurski MD, PhD
Chairman of the Polish Society of Osteoarthrology — Assistant Prof. Edward Czerwiński MD, PhD
Chairman of the Multibranch Forum of Osteoporosis – Prof. Roman Lorenc MD, PhD
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Introduction
Vitamin D is necessary to maintain appropriate calcium
and phosphate homeostasis in the body and to ensure
appropriate functioning of many tissues, organs and
cells, unrelated to mineral economy.
Vitamin D deficiency considered to be a risk factor for
the following [1–17]: cardiovascular diseases, metabolic syn-
drome and obesity, immunological system disorders, neo-
plasms, osteoporosis, bone fractures and falling incidents.
Figure 1 shows how vitamin D participates in vario-
us processes in the body. D-1,25-dihydroxy-vitamin D
[1,25(OH)2D], an active form of vitamin D, after binding with
the vitamin D receptor (VDR), exerts direct effects as a nuc-
lear transcriptive factor. 1,25(OH)2D acts also, either direc-
tly or indirectly, on more than 200 including those respon-
sible for renin and insulin synthesis, the release of cytoki-
nes from lymphocytes and for the growth and prolifera-
tion of vascular smooth muscles and cardiomyocytes [18].
Vitamin D influences the circulation via the renin–
angiotensin–aldosterone (RAA) system. Vitamin D de-
ficiency activate the RAA system, resulting in an excessi-
ve proliferation of vascular smooth muscle cells and left
ventricular hypertrophy. An association has been pro-
ven between hypovitaminosis D and myocardial infarc-
tion, cerebral stroke, cardiac insufficiency, hypertension,
the occurrence of eclampsia and vascular sclerosis.
Low vitamin D concentrations predispose to insulin
resistance, dysfunction of pancreatic beta-cells and, in
consequence, to obesity and the metabolic syndrome.
The active form of vitamin D is produced in macro-
phages in response to inflammatory reaction. It sup-
Figure 1. Effects of vitamin D3 (Schwalfenberg G. Can Fam Physician
2007; 53: 841–854)
Rycina 1. Efekty stosowania witaminy D3 (Schwalfenberg G. Can
Fam Physician 2007; 53: 841–854)
presses inflammatory processes, influencing the cells,
participating in autoimmunological reactions, and mo-
dulates lymphocyte responses. VDR receptor expres-
sion on macrophages enhances the processes of fago-
cytosis and increases cytokine production.
Decreased 1,25(OH)2D levels have been found in
multiple sclerosis, systemic lupus erythematosus and
psoriasis. Low vitamin D levels are a risk factor for the
development or progression of many neoplasms: bre-
ast, prostate, colon, kidney, lung and pancreatic can-
cer. Studies on tissue expression of 1a-hydroxylase co-
ding CYP27B1 gene and on the calcium receptor (CaR)
have demonstrated that local (extrarenal) synthesis of
active 1,25(OH)2D and the pool of extracellular Ca play
a significant role in carcinogenesis, regulating the pro-
cesses of proliferation and cell differentiation and sti-
mulating apoptosis. It is regarded as the key regulator
of cell functions in various types of tissues [8, 19, 20].
Vitamin D deficiency increases the risk of potential
falls and, in their consequence, of bone fractures. A rela-
tionship has been confirmed between sarcopenia (defect
of muscular fibres, replaced by adipose tissue), causing mu-
scle power decrease with tendency to falls and vitamin D
deficit. In this way, the anti-fracture efficacy of vitamin D
is shown in the population above 65 [13, 17, 21].
Metabolism of vitamin D
in physiological conditions
The term ‘vitamin D’ refers to the group of chemical
compounds of the steroid group with the general for-
mula C28H43OH. Of these compounds, vitamin D2 (er-
gocalciferol) and vitamin D3 (cholecalciferol) are the
most significant.
Vitamins D2 and D3 do not reveal biological activity.
They are initial substances which — in the body — un-
dergo an identical cycle of transformations with the
production of 1,25-dihydroxyvitamin D [1,25(OH)2D.]
— calcitriol, commonly perceived to be the most active
form of vitamin D.
We know that 1,25(OH)2D production takes place
not only in the kidneys but also in many cells and tissu-
es, demonstrating the activity of 1a-hydroxylase (a non-
classic effect). Renal synthesis is associated with the
maintenance of normal calcium-phosphate homeosta-
sis in the system (endocrine, systemic activity) by influ-
encing such target tissues as: intestine, kidneys, bone
(classical activity).
The locally produced 1,25(OH)2D vitamin controls
the proliferation and differentiation of cells and the pro-
cess of apoptosis in, among others, keratinocytes, ma-
crophages, muscle cells, mammary gland cells and in
cells of intestinal epithelium (para- and autocrine acti-
vity). This form is released into circulation and acts sys-
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temically in the course of sarcoidosis and tuberculosis.
1,25(OH)2D affects also the secretion of insulin by the
pancreas and of parathormone by the parathyroid
glands [22, 23].
Sources of vitamin D
Vitamin D3 is in 20% obtained from food (fish, eggs,
animal livers, dairy products) and in 80% from skin syn-
thesis as a product of skin 7-dehydrocholesterol trans-
formations, induced by ultraviolet (UV) radiation. This
synthesis proceeds in two stages:
— 7-dehydrocholesterol (7DHC) is converted into pro-
vitamin D (pre-D3) under the effects of UV radia-
tion with a wavelength of 290–320 nm (UVB);
— pro-vitamin D is, under the influence of body tem-
perature, converted into vitamin D3.
Vitamin D3, produced in deeper epidermal layers,
in the vicinity of blood and lymphatic vessels, is bound
by the vitamin D binding protein (DBP).
Vitamin D2 is found in vegetables and mushrooms.
The amount of 0.025 mg of pure calciferol is the In-
ternational Unit (IU) of vitamin.
In subjects with light pigmentation, 1 erythema dose
(1 MED) i.e. 1 dose of UV radiation, causing minimal skin
erythema leads to a ten-fold increase of vitamin D3 level
in blood serum, resulting from the release of approxima-
tely 30 mg of D3 from 1 square metre of body surface
within 24 hours. The level of vitamin D3, increased after
UV irradiation, returns to normal values after a few days.
In healthy subjects, it is accompanied by a slight increase
of 25(OH)D level, while in those with vitamin D deficits,
a triple increase of 25(OH)D in blood is observed.
The effectiveness of skin synthesis gets weaker as the
body ages; in subjects aged 70+, it is one quarter that of
young people given identical exposure to the sun. The
application of protective creams with anti-UVB filters also
reduces the skin synthesis of vitamin D3 [23, 24].
Metabolism of vitamin D
In contrast to the non-enzymatic synthesis of vitamin
D in skin, the transformation of vitamin D into 25(OH)D
and 1,25(OH)2D requires the presence of enzymes —
hydroxylases.
The first stage is hydroxylation of 25-hydroxyvita-
min in the liver in position 25 of the lateral chain, le-
ading to formation of metabolically inactive 25-hydro-
xyvitamin D — 25(OH)D in physiological concentra-
tions. Hydroxylation to active 1,25(OH)2D takes place
in the kidneys, where trace amounts of 24,25(OH)2D
and of 25,26(OH)2D are also formed [4,5].
The activity of hepatic 25-hydroxylase increases un-
der the effect of pro-vitamin D, DBP concentrations
and some drugs (e.g. antiepileptics) and decreases as
a result of the activity of the final metabolites of this
transformation. The activity of 1a-hydroxylase and/or
24a-hydroxylase increases under the influence of pa-
rathormone (PTH) and PTH-resembling peptide
(PTHrP), prostaglandins and reduced calcaemia and
phosphataemia.
The formation of active vitamin D form inhibits: the
increase of 1,25(OH)2D level, caused by PTH and PTHrP
deficits, hypercalcaemia, hyperphosphataemia, calcito-
nin and metabolic acidosis.
The hepatic metabolite, 25(OH)D, is eliminated by
24-hydroxylation and excretion with bile, following its
previous conjugation with glucuronic or sulphuric acid.
In physiological conditions, 3% of circulating metaboli-
tes are excreted with urine and faeces [23, 25].
Vitamin D deficiency
Definition
Table I presents a proposed terminology, used in the
evaluation of the system supply with vitamin D.
Causes of vitamin D deficits
See Table II for the causes of vitamin D deficiency.
Table I. Evaluation of the organism supply with vitamin D,
based on serum 25(OH)D concentration — terminology [23, 25]
Tabela I. Ocena zaopatrzenia w witaminę D na podstawie
stężenia 25(OH)D w surowicy — terminologia [23, 25]
Terminology Serum 25(OH)D
concentration
[nmol/L] [ng/mL]
Deficiency 0–25 0–10
Deficiency 25–50 10–20
Hypovitaminosis D 50–75 20–30
Recommended level 75–200 30–80
Toxic level > 250 > 100
Table II. Causes of vitamin D deficits
Tabela II. Przyczyny niedoboru witaminy D
Suppressed skin synthesis
Insufficient volume in diet and supplements
Obesity
Hepatic diseases
Renal diseases
Malabsorption syndromes
Genetic diseases
Anticonvulsant drugs
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Suppressed skin synthesis of vitamin D
and its insufficient supplementation with food
Without staying in the sun or an additional supplemen-
tation, vitamin D needs to be obtained in dietary com-
ponents: e.g. fatty fish, such as salmon (400 IU/100 g),
mackerel and sardines; cod-liver oil (400 IU/teaspoon);
and egg yolk (20 IU). Over recent years, changes for
the worse have been observed in dietary contents and
this has meant reduced consumption of vitamin D3; at
present, the components which dominate diets inclu-
de saturated fats, highly processed products and fast
foods which have a low vitamin D content.
Vitamin D production in the skin is limited in the
northern European climate during autumn and win-
ter. Because the angle of sun ray incidence is small, UVB
photons are absorbed by ozone in the atmosphere. The
synthesis is also suppressed by the use of creams with
sun-filters. Bright skin colour is associated with more
effective synthesis of vitamin B. The system’s ability to
produce vitamin D under UVB radiation decreases with
age [24, 26, 27].
Vitamin D deficiency in obese people
Obese subjects reveal significantly lower 25(OH)D con-
centration levels, partly because of vitamin D acumula-
tion in the adipose tissue and partly perhaps because
of avoiding direct exposure to sunlight with impaired
skin synthesis (vitamin D concentration after UVB ra-
diation is 57% lower than in normoweight subjects). It
may also be the result of an increased synthesis of D —
1,25(OH)2D, an active metabolite of vitamin D, in the
kidneys (which, in the negative feedback mechanism,
inhibits 25(OH)D production in the liver) [28, 29].
Vitamin D deficiency concomitant
with other diseases
In subjects with poor absorption syndrome, uncontrol-
led liver cirrhosis, renal diseases or who are on antico-
nvulsant drugs, systemic vitamin D deficits result from
elimination diet, impaired skin synthesis, disturbed
hydroxylation, excessive catabolism and decreased sen-
sitivity of target tissues to 1,25(OH)2D (e.g. in consequ-
ence of receptor defect).
Barbiturates, phenydantoin and pyramidone are
inducers of microsomal hepatic enzymes (e.g. glucuro-
nidases). The induction of hepatic vitamin D hydroxy-
lation accelerates the excretion of glucuronic vitamin D
inactive metabolites with bile.
Disturbances of vitamin D metabolism at the level
of 1a-hydroxylation lead to a considerable decrease of
1,25(OH)2D and to symptoms of vitamin D deficit. They
occur both in hereditary diseases (vitamin D-dependent
rickets of type I, hypophosphatemic rickets) and acqu-
ired diseases (chronic renal insufficiency, severe tubu-
lopathies, hypoparathyroidism, pseudo-hypoparathy-
roidism). The suppressed activity of 1a-hydroxylase is
a cause of reduced 1,25(OH)2D concentrations in oste-
oporosis, especially senile, and in disturbed secretion
of GH, prolactin and insulin [30].
Vitamin D-dependent rickets of type II is a repre-
sentative syndrome, caused by genetic disturbances of
1,25(OH)2D receptor.
Epidemiology of vitamin D deficiency
Hypovitaminosis D seems to be an epidemic in many
populations in the world. Vitamin D deficits are regar-
ded as one of the major health problems in children
and young adults, especially Afro-American, and in
middle-aged and elderly subjects. It has been determi-
ned that a concentration of 25(OH)D below 20 ng/mL
occurs in 36% of healthy subjects (aged 18–29), 42% of
black women (aged 15–49), 41% of out-patients (aged
49–83) and in almost 57% of internal in-patients in the
United States [31].
The prevalence of vitamin D deficiency in Europe is
even higher. Following biochemical measurements,
they have been diagnosed in 28–100% of healthy sub-
jects and in 70–100% of hospitalised adults [32].
In Poland, we have no useful population data on
the epidemiology of vitamin D deficits. However, defi-
cits have been identified, during the winter, in nine out
of every ten examined women in the OPTIFORD Pro-
ject, performed in five European countries [10]. In a stu-
dy performed on a small group of pregnant women in
the third trimester, the mean 25(OH)D concentration
was 9.93 ± 5.32 ng/mL during the winter and spring
[33, 34].
Vitamin D deficiency in mothers during pregnancy
result in hypovitaminosis D in newborns, because the
developing foetus and then the newborn is entirely
dependent on maternal stores of this vitamin. A strong
correlation has been demonstrated between 25(OH)D
concentrations in the mother and that in her newborn
baby [28, 35].
Vitamin D deficiency is fairly common in subjects
aged over 65 and in patients with osteoporosis. Stu-
dies of 8,532 post-menopausal women (mean age
74.2) from France, Belgium, Denmark, Italy, Poland,
Hungary, Great Britain, Spain and Germany have
shown a mean concentration of 24.4 ng/mL, with si-
gnificant differences between countries. The lowest
concentration of 25-hydroxyvitamin D was found in
France (25.75 ng/mL), while the highest was in Spain
(34 ng/mL). In the entire studied population, vitamin
D deficit concerned 79.6% or 32.1% of subjects,
according to whether 30 ng/mL or 20 ng/mL was re-
garded as the cut-off point [36, 37].
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Guidelines for vitamin D supplementation
in the population of adult subjects
Supplementation with vitamin D
1. An element of early prophylaxis in healthy popu-
lation.
2. Vitamin D deficit treatment for individual recom-
mendation in selected patients.
Supplementation with vitamin D in healthy
population
Cause. The causes of vitamin D supplementation in the
healthy population of Poland include reduced skin syn-
thesis (associated with latitude, ageing processes, the
use of sun-protection filters and lifestyle) and insuffi-
cient intake of vitamin D in the diet.
Goal. Supplementation with vitamin D is to main-
tain the level of 25(OH)D in serum above 30 ng/mL.
Prophylactics against vitamin D deficits
— Exposure to the sunlight.
— Oral vitamin D administration.
— Combined supplementation/skin irradiation and
vitamin D supplementation.
— The optimal conditions of skin exposure to UV ra-
diation in Poland occur from May until September.
The duration of staying in the sun necessary for
sufficient vitamin D synthesis is 20 minutes a day
(without the use of protective filters); exposing
unprotected face, hands and forearms (i.e. 15% of
body surface) to sunlight is perfectly adequate. An
alternative way to stimulate skin synthesis may be
irradiation with a UVB lamp (1 erythema dose, two
or three times a week).
— Oral vitamin D administration (minimum of
800–1,000 IU/day) is necessary during the period
of insufficient skin synthesis, i.e. in Poland from
October until April.
— Vitamin D (minimum of 800–1,000 IU/day) should
be administered to all subjects who do not expose
their skin, and to subjects aged over 65 throughout
the whole year for the age-related decrease of skin
synthesis and for the proven anti-fracture and anti-
fall effects of the vitamin (see Table III).
Supplementation of vitamin D
deficits in individual patients
Vitamin D deficiency may result not only because of
insufficient skin synthesis or low supplementation in
diet but also as a consequence of: disturbed absorption
in the digestive tract, decreased hydroxylation (liver or
kidney insufficiency), excessive catabolism (anticonvul-
sive drugs) or reduced sensitivity of target tissues to
1,25(OH)2D (vitamin D-resistant rickets of type II).
Where there is too little exposure to sunlight or too
little vitamin D intake in diet, it can be administered
orally. In subjects, either non-compliant with medical
recommendations or with poor tolerance of oral drug
administration, parenteral administration of vitamin D
is recommended.
In patients with disturbed absorption from the di-
gestive tract, vitamin D is administered in large doses
either orally or parenterally (the latter form is unavaila-
ble in Poland). The best effects of treating vitamin D
deficiency in this group of patients, just as in patients
with obesity combined with vitamin D deficit, are obta-
ined by stimulation of skin synthesis, using artificial
sources of UVB radiation and monitoring the levels of
25(OH)D every three months.
In patients with hepatic or renal dysfunctions, acti-
ve metabolites of vitamin D are used; in cases of calci-
diol deficiency for hepatic causes, calcifediol is used;
and in cases of calcitriol deficit for renal causes. alpha-
calcidiol is used (see Table IV).
A diagnosis of vitamin D deficiency requires the
application of much higher doses of vitamin D (thera-
peutic), differentiated according to degree of deficit
(see Table V). The therapeutic dose in severe depletion
may amount to at least 5,000 IU/day to 10,000 IU/day
(ab. 50,000 IU/week); in mild and moderate deficits it
could be 2,000–3,000 IU/day. The supplementation time
period varies between one and three months (depending
on deficit degree). Having obtained the optimal concen-
tration of 25(OH)D, a maintenance dose may be started.
In the course of treatment, it is necessary to monitor
25(OH)D in serum and, in severe deficits, it is necessary to
monitor calcium concentration, the activity of alkaline pho-
sphatase and of 24-h urinary calcium excretion (calciuria).
Table III. Supplementation of vitamin D for healthy adult population
Tabela III. Suplementacja witaminy D w populacji zdrowych dorosłych
Supplementation of vitamin D Skin synthesis Oral administration
Months X–III IV-IX X–III IV–IX
Adult subjects Up to age 65 – + 800–1.000 IU/d –
After 65 – –                                     800–1.000 IU/d
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Table IV. Causal treatment of patients with vitamin D deficit or disturbances of its metabolism
Tabela IV. Leczenie przyczynowe pacjentów z niedoborem witaminy D lub zaburzeniami jej metabolizmu
Therapy Vitamin D deficit - cause Hydroxylation disorders - cause
Nutrition Skin Øabsorption Liver Kidney
synthesis GI
UVB + + +
Oral administration of vit. D + + +
(large doses)
Parenteral administration of vit. D +
25(OH)D +
1a(OH)D
1,25(OH)2D +
GI — gastrointestinal tract
Table V. Vitamin D deficiency (treatment/supplementation)
Tabela V. Niedobory witaminy D (leczenie/suplementacja)
Serum level of 25(OH)D < 10 ng/mL 10–20 ng/mL 20–30 ng/mL > 30 ng/mL
Deficit degree Severe Moderate Mild Optimal concentration
Therapeutic dose of vitamin D* + + + –
Prophylactic dose of vitamin D – – – +
Follow-up every three months
25(OH)D + + – –
Fas +
Cas +
calciuria +
*supplementation time — until an optimal level is obtained for the pleiotropic effect of vitamin D (25(OH)D > 30 mg/mL)
Table VI. Vitamin D3 commercial forms available on the
Polish market
Tabela VI. Postacie handlowe witaminy D3 dostępne na
polskim rynku
Agent Dose in 1 mL Dose in one
drop or tablet
Devikap (Medana) 15.000 IU 500 IU
10 mL — drops
Juvit D3 (Hasco-Lek) 20.000 IU 590 IU
10 mL — drops
Vigantol (Merk) 20.000 IU 670 IU
10 mL — drops
Vigantoletten 500 (Merk) n/a 500 IU
tablet
Vigantoletten 1000 (Merk) n/a 1000 IU
tablet
Vta D (Vitis Pharma) n/a 400 IU
Table VII. Active metabolites and analogues of vitamin D
Tabela VII. Aktywne metabolity i analogi witaminy D
Name Agent Dose in  1 mL/tablet
25(OH)D Devisol 25 0.15 mg
calcifediol  (drops)
1a(OH)D Alfadiol 0.25 mg
alphacalcidol  Alfakalcydol IF    1 mg
 (tabl.)
1,25(OH)2D Kalcytriol 0.25 mg
calcitriol (tabl.)
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Compensation of vitamin D
deficiency — practical remarks
— The effect of vitamin D2 is 30% lower than that of
vitamin D3.
— Vitamin D can be administered alternatively in ap-
propriate doses: every week, or every two or four
weeks (it acumulates in the system), as it ensures
better compliance.
— The supplementing dose of vitamin D should be
higher in elderly patients, in those with obesity, in-
habitants of more northerly parts of the world, du-
ring autumn and winter and in subjects with dark
skin pigmentation who use creams which protect
against UVB which affects vitamin D metabolism.
— Calcitriol and alphacalcidol are not indicated to sup-
plement vitamin D deficits in healthy people. They
should be applied in disorders of vitamin D hydro-
xylation as a result of chronic liver or renal disease.
— Vitamin D should be administered together with
meals, for more effective absorbtion.
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